AMSTERDAM, Netherlands, Feb. 3 /PRNewswire/ -- Exponential Biotherapies' Food Safety Division (http://www.expobio.com/) announced that it has opened its Phage Service Center in collaboration with Primagen Holding BV (http://www.primagen.com/) near Schiphol Airport in Amsterdam, the Netherlands. The center will conduct the technical servicing of industrial food clients, and specialist scientists will work on the further improvement of food safety applications of Exponential Biotherapies' proprietary technologies. The Phage Service Center is equipped with state of the art laboratory facilities, automated data warehousing, and is ISO 9001:2000 certified.
Phages are "friendly" viruses that target and kill bacteria. They are abundant in the environment - including in our food and water. Through use of the right phage strains, and in the right amounts, Exponential Biotherapies has developed a "green" approach to controlling bacterial pathogens in the food supply. The company has pioneered this approach, which enables food producers to protect their products without having to use agents (such as antibiotics) that can be harmful to health as well as to the environment.
All of Exponential Biotherapies' materials and findings from its global research programs will be consolidated at the Center's repository. In addition the Center will be responsible for the supervision and coordination of the Quality Assurance program for all products of Exponential Biotherapies' Food safety Division.
"Because our customers are located around the world, the highest standard of quality and consistency in our products and service is necessary", states the Division's Chief Operating Officer, Dirk de Meester. "The opening of the Center is a clear commitment to the further improvement of delivering outstanding service to our clients and exceeding their expectations"
"Housing of the Phage Service Center has given Primagen an excellent business partner in the phage and microbiology field" says Dr. Bob van Gemen, CEO of Primagen. "With this collaboration we make better use of our state of the art facilities and we can leverage some of our expertise from Quality Assurance programs in a new field".
About Exponential Biotherapies
Exponential Biotherapies, Inc is a privately held biopharmaceutical company focused on the development and commercialization of new anti-bacterial and anti-inflammatory agents. Exponential Biotherapies' success is built on a
unique combination of an international scientific network and excellent capabilities for product development, manufacturing and marketing. The company is solution-driven and selects those leads for potential concepts in which proprietary intellectual property can be leveraged rapidly from bench to market.
Primagen Holding B.V. is a privately held company headquartered in Amsterdam, The Netherlands. Primagen designs, develops and commercializes molecular tests that have high, individualized predictive value and improve the quality of life for patients suffering from life-threatening diseases, such as infections, AIDS and cancer. Primagen has two marketed molecular product lines: The Retina(TM) Mitox(TM) products measure mitochondrial DNA and RNA in clinical samples with unmatched accuracy and predict the onset of clinical symptoms as a result of mitochondrial toxicity. The Retina(TM) Rainbow products enable detection of all circulating HIV-1 subtypes and, combined with Primagen's proprietary dried bloodspot filter paper technology, bring HIV-1 viral load measurement to Africa and other resource-poor environments. Primagen is expanding its product portfolio in the area of virus-induced diseases, where it has discovered and patented two new human viruses in 2003.
Exponential Biotherapies, Inc
CONTACT: Dirk de Meester of Exponential Biotherapies, +31-64-604-8503,or Fax, +31-84-223-7292, or email@example.com; or Esther de Rooij ofPrimagen, +31-20-566-8569, or Fax, +31-20-566-9081, or firstname.lastname@example.org